• Overview
  • Eligibility
  • More info
  • Locations

(NCT03025958)

Radiation Plus Concurrent Nimotuzumab in Elderly Patients With Locoregionally Advanced Nasopharyngeal Carcinoma
  • Drug: Nimotuzumab
    • Radiation: Radiation
      Ages eligible for Study
      65 Years and older
      Genders eligible for Study
      All
      Accepts Healthy Volunteers
      No
      Inclusion Criteria:
      • Previously untreated and histologically confirmed locoregionally advanced nasopharyngeal carcinoma
      Exclusion Criteria:
      • A history of another invasive cancer, prior RT to the head and neck area, prior cytotoxic chemotherapy or anti-EGFR therapy or the presence of any serious medical conditions, supposed to live less than 6 months.
      Elderly patients with locoregionally advanced nasopharyngeal carcinoma were given an initial dose of nimotuzumab (200 mg) 7days before receiving concurrent radiotherapy, weekly nimotuzumab (200 mg/week).

      1 locations

      China (1)
      • Xiaozhong Chen
        recruiting
        Hangzhou, Zhejiang, China, 310022
      Status:
      recruiting
      Type:
      Interventional
      Phase:
      Start:
      31 December, 2016
      Updated:
      18 January, 2017
      Participants:
      30
      Apply
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!